Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
14 juil. 2021 09h00 HE
|
Auris Medical AG
Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs....
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
28 juin 2021 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection,...
Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India
01 juin 2021 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU
25 mai 2021 09h00 HE
|
Auris Medical AG
Meeting essential requirements for marketing BentrioTM in Europe under CE markOn track for first product launch in Europe towards end of Q2 2021 Hamilton, Bermuda, May 25, 2021 – Auris Medical...
Auris Medical Provides Update on Bentrio Program in Allergy
07 mai 2021 09h05 HE
|
Auris Medical AG
BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitisClinically relevant and significant reduction in nasal symptomsSuperior efficacy ratings by patients and clinicians...
Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
13 avr. 2021 07h45 HE
|
Auris Medical AG
Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...